An exploratory study on the anti-inflammatory effects of fucoidan in relation to quality of life in advanced cancer patients

An exploratory study on the anti-inflammatory effects of fucoidan in relation to quality of life in advanced cancer patients - An exploratory study on the anti-inflammatory effects of fucoidan in relation to quality of life in advanced cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024066

Enrollment

Registered

2016-09-15

Start date

2014-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced cancer

Interventions

receive 400 ml/day of fucoidan (Trade name: Power Fucoidan, Daiichi Sangyo, Co. Ltd. Osaka, Japan) for at least 4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) clinically diagnosed with inoperable metastatic cancer, (2) aged over 20 years, (3) ambulatory as an outpatient with normal food intake for at least 4 weeks during the study,

Exclusion criteria

Exclusion criteria: with serious dysfunction of vital organs.

Design outcomes

Primary

Measure	Time frame
Changes in inflammatory biomarkers including high-sensitivity CRP, and pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alfa) during the study period of 4w.	—

Secondary

Measure	Time frame
Changes in QOL scores using EORTC QLQ-C30 during the study period of 4w.	—

Countries

Japan

Contacts

Public ContactHidenori Takahashi

University of the Ryukyus Hospital Division of Community-based Medicine and Primary Care

bzr06263@med.u-ryukyu.ac.jp098-895-1331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026